Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
unknown
📅 Published: 2026-01-07 13:33
📰 Source: Yahoo
📝 Words: 16
📝 Article Content
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
📄 Summary
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-01-09 00:08:09
Updated At:
2026-01-09 00:08:09
Scraping Job ID:
N/A
Stock Mentions:
AMGN - Amgen Inc.
Relevance: N/A